Listed

OS Therapies Inc

OSTXNYSECIK 1795091HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$8.6m, Q2 FY2026
Net income−$8.6m, Q2 FY2026
OS Therapies Inc, income statement, quarterly
Line itemUnitperiod not labelled2023-09-30period not labelled2023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Research and development$m0.5Research and development, period not labelled, three months to 2023-09-30$454.5k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-15, accession 0001213900-24-098760.Report this figure1.0Research and development, period not labelled, three months to 2023-12-31$1.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-31, accession 0001213900-25-026238. Derived: 12-month figure less the 9-month figure.Report this figure0.4Research and development, Q1 FY2024, three months to 2024-03-31$361.8k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-15, accession 0001213900-25-044336.Report this figure0.4Research and development, Q2 FY2024, three months to 2024-06-30$396.6k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-18, accession 0001213900-25-077916.Report this figure1.2Research and development, Q3 FY2024, three months to 2024-09-30$1.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-14, accession 0001213900-25-110829.Report this figure0.9Research and development, Q4 FY2024, three months to 2024-12-31$870.5k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-31, accession 0001213900-26-036629. Derived: 12-month figure less the 9-month figure.Report this figure1.3Research and development, Q1 FY2025, three months to 2025-03-31$1.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-18, accession 0001213900-26-058070.Report this figure2.5Research and development, Q2 FY2025, three months to 2025-06-30$2.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-14, accession 0001213900-26-090238.Report this figure3.8Research and development, Q3 FY2025, three months to 2025-09-30$3.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-14, accession 0001213900-25-110829.Report this figure8.8Research and development, Q4 FY2025, three months to 2025-12-31$8.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-31, accession 0001213900-26-036629. Derived: 12-month figure less the 9-month figure.Report this figure7.4Research and development, Q1 FY2026, three months to 2026-03-31$7.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-18, accession 0001213900-26-058070.Report this figure6.1Research and development, Q2 FY2026, three months to 2026-06-30$6.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-14, accession 0001213900-26-090238.Report this figure
Operating income$m(0.6)Operating income, period not labelled, three months to 2023-09-30−$622.2k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-15, accession 0001213900-24-098760.Report this figure(1.2)Operating income, period not labelled, three months to 2023-12-31−$1.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-31, accession 0001213900-25-026238. Derived: 12-month figure less the 9-month figure.Report this figure(0.6)Operating income, Q1 FY2024, three months to 2024-03-31−$630.2k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-15, accession 0001213900-25-044336.Report this figure(0.8)Operating income, Q2 FY2024, three months to 2024-06-30−$779.8k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-18, accession 0001213900-25-077916.Report this figure(2.4)Operating income, Q3 FY2024, three months to 2024-09-30−$2.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-14, accession 0001213900-25-110829.Report this figure(3.0)Operating income, Q4 FY2024, three months to 2024-12-31−$3.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-31, accession 0001213900-26-036629. Derived: 12-month figure less the 9-month figure.Report this figure(5.0)Operating income, Q1 FY2025, three months to 2025-03-31−$5.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-18, accession 0001213900-26-058070.Report this figure(4.8)Operating income, Q2 FY2025, three months to 2025-06-30−$4.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001213900-26-090238.Report this figure(6.9)Operating income, Q3 FY2025, three months to 2025-09-30−$6.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-14, accession 0001213900-25-110829.Report this figure(12.0)Operating income, Q4 FY2025, three months to 2025-12-31−$12.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-31, accession 0001213900-26-036629. Derived: 12-month figure less the 9-month figure.Report this figure(10.2)Operating income, Q1 FY2026, three months to 2026-03-31−$10.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-18, accession 0001213900-26-058070.Report this figure(8.6)Operating income, Q2 FY2026, three months to 2026-06-30−$8.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001213900-26-090238.Report this figure
Interest expense$m1.4Interest expense, period not labelled, three months to 2023-09-30$1.4m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2024-11-15, accession 0001213900-24-098760.Report this figure0.3Interest expense, period not labelled, three months to 2023-12-31$307.5k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2025-03-31, accession 0001213900-25-026238. Derived: 12-month figure less the 9-month figure.Report this figure0.8Interest expense, Q1 FY2024, three months to 2024-03-31$828.8k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-05-20, accession 0001213900-24-045141.Report this figure0.8Interest expense, Q2 FY2024, three months to 2024-06-30$777.7k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-08-18, accession 0001213900-25-077916.Report this figure0.4Interest expense, Q3 FY2024, three months to 2024-09-30$437.8k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-14, accession 0001213900-25-110829.Report this figure0.0Interest expense, Q4 FY2024, three months to 2024-12-31$7.6k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-03-31, accession 0001213900-26-036629. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reported0.1Interest expense, Q1 FY2026, three months to 2026-03-31$75.3k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-18, accession 0001213900-26-058070.Report this figure0.0Interest expense, Q2 FY2026, three months to 2026-06-30$5.6k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-14, accession 0001213900-26-090238.Report this figure
Net income$m(2.0)Net income, period not labelled, three months to 2023-09-30−$2.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-15, accession 0001213900-24-098760.Report this figure(1.5)Net income, period not labelled, three months to 2023-12-31−$1.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-31, accession 0001213900-25-026238. Derived: 12-month figure less the 9-month figure.Report this figure(1.5)Net income, Q1 FY2024, three months to 2024-03-31−$1.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001213900-25-110829.Report this figure(1.6)Net income, Q2 FY2024, three months to 2024-06-30−$1.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001213900-25-110829.Report this figure(2.9)Net income, Q3 FY2024, three months to 2024-09-30−$2.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001213900-25-110829.Report this figure(3.0)Net income, Q4 FY2024, three months to 2024-12-31−$3.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-31, accession 0001213900-26-036629. Derived: 12-month figure less the 9-month figure.Report this figure(3.9)Net income, Q1 FY2025, three months to 2025-03-31−$3.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001213900-26-090238.Report this figure(4.5)Net income, Q2 FY2025, three months to 2025-06-30−$4.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001213900-26-090238.Report this figure(6.9)Net income, Q3 FY2025, three months to 2025-09-30−$6.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001213900-25-110829.Report this figure(13.5)Net income, Q4 FY2025, three months to 2025-12-31−$13.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-31, accession 0001213900-26-036629. Derived: 12-month figure less the 9-month figure.Report this figure(10.4)Net income, Q1 FY2026, three months to 2026-03-31−$10.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001213900-26-090238.Report this figure(8.6)Net income, Q2 FY2026, three months to 2026-06-30−$8.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001213900-26-090238.Report this figure
Diluted EPS$ per share(0.38)Diluted EPS, period not labelled, three months to 2023-09-30−$0.38 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-15, accession 0001213900-24-098760.Report this figurenot reported(0.25)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.25 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-15, accession 0001213900-25-044336.Report this figure(0.26)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.26 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-18, accession 0001213900-25-077916.Report this figure(0.18)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.18 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-14, accession 0001213900-25-110829.Report this figurenot reported(0.18)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.18 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-18, accession 0001213900-26-058070.Report this figure(0.19)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.19 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001213900-26-090238.Report this figure(0.21)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.21 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-14, accession 0001213900-25-110829.Report this figurenot reported(0.27)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.27 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-18, accession 0001213900-26-058070.Report this figure(0.20)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.20 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001213900-26-090238.Report this figure
Basic EPS$ per share(0.38)Basic EPS, period not labelled, three months to 2023-09-30−$0.38 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-15, accession 0001213900-24-098760.Report this figurenot reported(0.25)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.25 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-15, accession 0001213900-25-044336.Report this figure(0.26)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.26 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-18, accession 0001213900-25-077916.Report this figure(0.18)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.18 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-14, accession 0001213900-25-110829.Report this figurenot reported(0.18)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.18 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-18, accession 0001213900-26-058070.Report this figure(0.19)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.19 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-14, accession 0001213900-26-090238.Report this figure(0.21)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.21 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-14, accession 0001213900-25-110829.Report this figurenot reported(0.27)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.27 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-18, accession 0001213900-26-058070.Report this figure(0.20)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.20 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-14, accession 0001213900-26-090238.Report this figure

Balance sheet

Cash and equivalents$205.0k, Q2 FY2026
Shareholders' equity−$11.9m, Q2 FY2026
OS Therapies Inc, balance sheet, quarterly
Line itemUnitperiod not labelled2023-12-31period not labelled2024-03-07Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m0.0Cash and equivalents, period not labelled, at 2023-12-31$39.0k. XBRL concept us-gaap:Cash. 10-K filed 2025-03-31, accession 0001213900-25-026238.Report this figurenot reported0.1Cash and equivalents, Q1 FY2024, at 2024-03-31$100.2k. XBRL concept us-gaap:Cash. 10-Q filed 2024-05-20, accession 0001213900-24-045141.Report this figure0.1Cash and equivalents, Q2 FY2024, at 2024-06-30$94.9k. XBRL concept us-gaap:Cash. 10-Q filed 2024-08-14, accession 0001213900-24-069063.Report this figure1.9Cash and equivalents, Q3 FY2024, at 2024-09-30$1.9m. XBRL concept us-gaap:Cash. 10-Q filed 2024-11-15, accession 0001213900-24-098760.Report this figure5.5Cash and equivalents, FY2024, at 2024-12-31$5.5m. XBRL concept us-gaap:Cash. 10-K filed 2026-03-31, accession 0001213900-26-036629.Report this figure3.0Cash and equivalents, Q1 FY2025, at 2025-03-31$3.0m. XBRL concept us-gaap:Cash. 10-Q filed 2025-05-15, accession 0001213900-25-044336.Report this figure2.8Cash and equivalents, Q2 FY2025, at 2025-06-30$2.8m. XBRL concept us-gaap:Cash. 10-Q filed 2025-08-18, accession 0001213900-25-077916.Report this figurenot reported0.3Cash and equivalents, FY2025, at 2025-12-31$269.8k. XBRL concept us-gaap:Cash. 10-Q filed 2026-08-14, accession 0001213900-26-090238.Report this figure0.9Cash and equivalents, Q1 FY2026, at 2026-03-31$917.6k. XBRL concept us-gaap:Cash. 10-Q filed 2026-05-18, accession 0001213900-26-058070.Report this figure0.2Cash and equivalents, Q2 FY2026, at 2026-06-30$205.0k. XBRL concept us-gaap:Cash. 10-Q filed 2026-08-14, accession 0001213900-26-090238.Report this figure
Current assets$m0.8Current assets, period not labelled, at 2023-12-31$790.0k. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-31, accession 0001213900-25-026238.Report this figurenot reported1.0Current assets, Q1 FY2024, at 2024-03-31$1.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-20, accession 0001213900-24-045141.Report this figure1.3Current assets, Q2 FY2024, at 2024-06-30$1.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-14, accession 0001213900-24-069063.Report this figure2.0Current assets, Q3 FY2024, at 2024-09-30$2.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-15, accession 0001213900-24-098760.Report this figure5.5Current assets, FY2024, at 2024-12-31$5.5m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-31, accession 0001213900-26-036629.Report this figure4.1Current assets, Q1 FY2025, at 2025-03-31$4.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-15, accession 0001213900-25-044336.Report this figure3.6Current assets, Q2 FY2025, at 2025-06-30$3.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-18, accession 0001213900-25-077916.Report this figure2.3Current assets, Q3 FY2025, at 2025-09-30$2.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-14, accession 0001213900-25-110829.Report this figure0.3Current assets, FY2025, at 2025-12-31$332.9k. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001213900-26-090238.Report this figure0.9Current assets, Q1 FY2026, at 2026-03-31$917.6k. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-18, accession 0001213900-26-058070.Report this figure3.6Current assets, Q2 FY2026, at 2026-06-30$3.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001213900-26-090238.Report this figure
Total assets$m0.8Total assets, period not labelled, at 2023-12-31$798.1k. XBRL concept us-gaap:Assets. 10-K filed 2025-03-31, accession 0001213900-25-026238.Report this figurenot reported1.0Total assets, Q1 FY2024, at 2024-03-31$1.0m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-20, accession 0001213900-24-045141.Report this figure1.3Total assets, Q2 FY2024, at 2024-06-30$1.3m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-14, accession 0001213900-24-069063.Report this figure2.0Total assets, Q3 FY2024, at 2024-09-30$2.0m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-15, accession 0001213900-24-098760.Report this figure5.5Total assets, FY2024, at 2024-12-31$5.5m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-31, accession 0001213900-26-036629.Report this figure4.2Total assets, Q1 FY2025, at 2025-03-31$4.2m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-15, accession 0001213900-25-044336.Report this figure10.3Total assets, Q2 FY2025, at 2025-06-30$10.3m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-18, accession 0001213900-25-077916.Report this figure9.0Total assets, Q3 FY2025, at 2025-09-30$9.0m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-14, accession 0001213900-25-110829.Report this figure6.8Total assets, FY2025, at 2025-12-31$6.8m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001213900-26-090238.Report this figure7.3Total assets, Q1 FY2026, at 2026-03-31$7.3m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-18, accession 0001213900-26-058070.Report this figure9.9Total assets, Q2 FY2026, at 2026-06-30$9.9m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001213900-26-090238.Report this figure
Current liabilities$m24.7Current liabilities, period not labelled, at 2023-12-31$24.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-31, accession 0001213900-25-026238.Report this figurenot reported26.5Current liabilities, Q1 FY2024, at 2024-03-31$26.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-20, accession 0001213900-24-045141.Report this figure28.3Current liabilities, Q2 FY2024, at 2024-06-30$28.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-14, accession 0001213900-24-069063.Report this figure2.6Current liabilities, Q3 FY2024, at 2024-09-30$2.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-15, accession 0001213900-24-098760.Report this figure4.6Current liabilities, FY2024, at 2024-12-31$4.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-31, accession 0001213900-26-036629.Report this figure3.5Current liabilities, Q1 FY2025, at 2025-03-31$3.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-15, accession 0001213900-25-044336.Report this figure3.5Current liabilities, Q2 FY2025, at 2025-06-30$3.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-18, accession 0001213900-25-077916.Report this figure4.1Current liabilities, Q3 FY2025, at 2025-09-30$4.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-14, accession 0001213900-25-110829.Report this figure11.8Current liabilities, FY2025, at 2025-12-31$11.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001213900-26-090238.Report this figure17.0Current liabilities, Q1 FY2026, at 2026-03-31$17.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-18, accession 0001213900-26-058070.Report this figure20.6Current liabilities, Q2 FY2026, at 2026-06-30$20.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001213900-26-090238.Report this figure
Total liabilities$m24.8Total liabilities, period not labelled, at 2023-12-31$24.8m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-31, accession 0001213900-25-026238.Report this figurenot reported26.6Total liabilities, Q1 FY2024, at 2024-03-31$26.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-20, accession 0001213900-24-045141.Report this figure28.4Total liabilities, Q2 FY2024, at 2024-06-30$28.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-14, accession 0001213900-24-069063.Report this figure2.7Total liabilities, Q3 FY2024, at 2024-09-30$2.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-15, accession 0001213900-24-098760.Report this figure4.7Total liabilities, FY2024, at 2024-12-31$4.7m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-31, accession 0001213900-26-036629.Report this figure3.6Total liabilities, Q1 FY2025, at 2025-03-31$3.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-15, accession 0001213900-25-044336.Report this figure3.6Total liabilities, Q2 FY2025, at 2025-06-30$3.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-18, accession 0001213900-25-077916.Report this figure4.2Total liabilities, Q3 FY2025, at 2025-09-30$4.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-14, accession 0001213900-25-110829.Report this figure11.9Total liabilities, FY2025, at 2025-12-31$11.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001213900-26-090238.Report this figure17.1Total liabilities, Q1 FY2026, at 2026-03-31$17.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-18, accession 0001213900-26-058070.Report this figure20.7Total liabilities, Q2 FY2026, at 2026-06-30$20.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001213900-26-090238.Report this figure
Short-term borrowings$mnot reported0.1Short-term borrowings, period not labelled, at 2024-03-07$100.0k. XBRL concept us-gaap:ShortTermBorrowings. 10-K filed 2026-03-31, accession 0001213900-26-036629.Report this figure0.1Short-term borrowings, Q1 FY2024, at 2024-03-31$100.0k. XBRL concept us-gaap:ShortTermBorrowings. 10-Q filed 2024-05-20, accession 0001213900-24-045141.Report this figure0.3Short-term borrowings, Q2 FY2024, at 2024-06-30$250.0k. XBRL concept us-gaap:ShortTermBorrowings. 10-Q filed 2024-08-14, accession 0001213900-24-069063.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m(24.0)Shareholders' equity, period not labelled, at 2023-12-31−$24.0m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-31, accession 0001213900-26-036629.Report this figurenot reported(25.5)Shareholders' equity, Q1 FY2024, at 2024-03-31−$25.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001213900-25-110829.Report this figure(27.1)Shareholders' equity, Q2 FY2024, at 2024-06-30−$27.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001213900-25-110829.Report this figure(0.7)Shareholders' equity, Q3 FY2024, at 2024-09-30−$707.1k. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001213900-25-110829.Report this figure(3.3)Shareholders' equity, FY2024, at 2024-12-31−$3.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001213900-26-090238.Report this figure(4.2)Shareholders' equity, Q1 FY2025, at 2025-03-31−$4.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001213900-26-090238.Report this figure4.9Shareholders' equity, Q2 FY2025, at 2025-06-30$4.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001213900-26-090238.Report this figure3.6Shareholders' equity, Q3 FY2025, at 2025-09-30$3.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001213900-25-110829.Report this figure(6.1)Shareholders' equity, FY2025, at 2025-12-31−$6.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001213900-26-090238.Report this figure(10.8)Shareholders' equity, Q1 FY2026, at 2026-03-31−$10.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001213900-26-090238.Report this figure(11.9)Shareholders' equity, Q2 FY2026, at 2026-06-30−$11.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001213900-26-090238.Report this figure

Cash flow

Operating cash flow−$5.5m, Q2 FY2026
Capital expenditure$0, Q4 FY2025
OS Therapies Inc, cash flow, quarterly
Line itemUnitperiod not labelled2023-09-30period not labelled2023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$k(877)Operating cash flow, period not labelled, three months to 2023-09-30−$876.6k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-15, accession 0001213900-24-098760. Derived: 9-month figure less the 6-month figure.Report this figure(871)Operating cash flow, period not labelled, three months to 2023-12-31−$871.2k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-31, accession 0001213900-25-026238. Derived: 12-month figure less the 9-month figure.Report this figure(642)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$641.7k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-15, accession 0001213900-25-044336.Report this figure(881)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$881.2k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-18, accession 0001213900-25-077916. Derived: 6-month figure less the 3-month figure.Report this figure(3,385)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$3.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-14, accession 0001213900-25-110829. Derived: 9-month figure less the 6-month figure.Report this figure(2,375)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$2.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-31, accession 0001213900-26-036629. Derived: 12-month figure less the 9-month figure.Report this figure(3,442)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$3.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-18, accession 0001213900-26-058070.Report this figure(2,360)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$2.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001213900-26-090238. Derived: 6-month figure less the 3-month figure.Report this figure(4,706)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$4.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-14, accession 0001213900-25-110829. Derived: 9-month figure less the 6-month figure.Report this figure(3,730)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$3.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-31, accession 0001213900-26-036629. Derived: 12-month figure less the 9-month figure.Report this figure(4,564)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$4.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-18, accession 0001213900-26-058070.Report this figure(5,533)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$5.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001213900-26-090238. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$k0.0Capital expenditure, period not labelled, three months to 2023-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-15, accession 0001213900-24-098760. Derived: 9-month figure less the 6-month figure.Report this figurenot reportednot reportednot reportednot reportednot reported150Capital expenditure, Q1 FY2025, three months to 2025-03-31$150.0k. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2026-05-18, accession 0001213900-26-058070.Report this figure316Capital expenditure, Q2 FY2025, three months to 2025-06-30$316.4k. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2026-08-14, accession 0001213900-26-090238. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2025-11-14, accession 0001213900-25-110829. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-K filed 2026-03-31, accession 0001213900-26-036629. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported

Shares

Diluted shares (weighted)43.90m, Q2 FY2026
OS Therapies Inc, shares, quarterly
Line itemUnitperiod not labelled2023-06-30period not labelled2023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares5.3Diluted shares (weighted), period not labelled, three months to 2023-06-305,340,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-14, accession 0001213900-24-069063.Report this figure5.3Diluted shares (weighted), period not labelled, three months to 2023-09-305,340,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-15, accession 0001213900-24-098760.Report this figure6.0Diluted shares (weighted), Q1 FY2024, three months to 2024-03-315,991,041 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-15, accession 0001213900-25-044336.Report this figure6.0Diluted shares (weighted), Q2 FY2024, three months to 2024-06-305,991,041 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-18, accession 0001213900-25-077916.Report this figure15.9Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3015,897,460 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-14, accession 0001213900-25-110829.Report this figure21.2Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3121,249,423 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-18, accession 0001213900-26-058070.Report this figure25.1Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3025,114,460 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-14, accession 0001213900-26-090238.Report this figure32.0Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3031,956,686 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-14, accession 0001213900-25-110829.Report this figure38.7Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3138,674,663 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-18, accession 0001213900-26-058070.Report this figure43.9Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3043,904,159 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-14, accession 0001213900-26-090238.Report this figure

Shares outstanding: 46.13mShares outstanding, period not labelled, at 2026-08-1246,125,825 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-14, accession 0001213900-26-090238.Report this figure at Aug 12, 2026, from the cover of the 10-Q filed Aug 14, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. Listed shows no prices and gives no investment advice.